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Abstract
Background: SKI and SnoN proteins have been shown to inhibit TGF-b signaling, acting both as transcriptional
co-repressors in the cell nucleus, and as sequestrators of SMAD proteins in the cytoplasm. TGF-b, on the other
hand, induces rapid, proteasome-mediated, degradation of both proteins. How elevated SKI and SnoN protein
levels co-exist with active autocrine TGF-b signaling in cancer cells is yet to be understood.
Results: In this study, we found elevated SKI and SnoN protein levels in a panel of melanoma cell lines, as
compared to normal melanocytes. There was no correlation between SKI protein content and the capacity of
melanoma cells to invade Matrigel™, to form subcutaneous tumors, or to metastasize to bone after intracardiac
inoculation into nude mice. Nor did we find a correlation between SKI expression and histopathological staging of
human melanoma. TGF-b induced a rapid and dose-dependent degradation of SKI protein, associated with
SMAD3/4 specific transcriptional response and induction of pro-metastatic target genes, partially prevented by
pharmacologic blockade of proteasome activity. SKI knockdown in 1205Lu melanoma cells did not alter their
invasive capacity or transcriptional responses to TGF-b, and did not allow p21 expression in response to TGF-b or
reveal any growth inhibitory activity of TGF-b.
Conclusions: Despite high expression in melanoma cells, the role of SKI in melanoma remains elusive: SKI does
not efficiently interfere with the pro-oncogenic activities of TGF-b, unless stabilized by proteasome blockade. Its
highly labile nature makes it an unlikely target for therapeutic intervention.
Background
Transforming growth factor-b (TGF-b)s u p e r f a m i l y
members signal via membrane-bound heteromeric ser-
ine-threonine kinase receptor complexes. Upon ligand
binding, receptor activation leads to phosphorylation of
cytoplasmic protein substrates of the SMAD family and
subsequent accumulation in the nucleus where they act
as transcription factors to regulate target gene expres-
sion [1-3]. TGF-b acts as a tumor suppressor by pro-
moting cell cycle arrest or apoptosis of normal epithelial
cells during early stages of carcinogenesis, while at later
stages of tumorigenesis, it functions as a tumor promo-
ter, inducing neoplastic cell invasiveness and metastasis
through a process referred to as epithelial to mesenchy-
mal transdifferentiation (EMT), and via modulation of
the extracellular tumor microenvironment, production
of chemokines and recruitment of immature bone
marrow-derived myeloid cells to the invasive front
of tumors, and inhibition of anti-tumoral immune
defenses [4-8].
Members of the SKI family of proto-oncoproteins are
involved in regulation of cellular transformation and dif-
ferentiation [9]. SKI was originally identified as the
transforming protein (v-ski) of the avian Sloan-Kettering
virus, whose overexpression promotes anchorage-inde-
pendent growth of chicken and quail embryo fibroblasts
[10]. SKI (and SnoN) proteins are also important nega-
tive regulators of the TGF-b signaling cascade [11-13].
In the nucleus, SKI proteins repress SMAD ability to
transactivate TGF-b target genes by disrupting active
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SMAD4, by recruiting a transcriptional repressor com-
plex containing N-CoR SMRT, Sin3A, and HDAC-1,
and by blocking the binding of transcriptional coactiva-
tors [14-16]. SKI may also localize in the cytoplasm of
tumor cells [17], where it may interfere with TGF-b sig-
naling by sequestering SMAD proteins and preventing
their nuclear accumulation in response to TGF-b,a sw e
demonstrated in the case of SnoN [18]. The ability of
SnoN and SKI to antagonize TGF-b-induced growth
arrest is thought to be important for their transforming
activity [19]. Inversely, other reports have shown cell-
type specific effects of SnoN as a mediator of TGF-b
signaling [20], and identified ING2 as a mediator of
SnoN effects to promote TGF-b-driven transcription
[21], thereby emphasizing the complexity of the interac-
tion between SKI family members and TGF-b signaling.
Furthermore, expression levels of SKI family members
m a yb ed o w n r e g u l a t e db yT G F - b, as the latter rapidly
induces SKI protein poly-ubiquitination and degradation
in a SMAD- and proteasome-dependent manner, allow-
ing TGF-b target gene transactivation [22-29].
Consistent with a potential oncogenic role, SKI and
SnoN are often expressed at high levels in various
human cancers cells derived from melanoma, esophageal
cancer, pancreatic cancer and leukemia, due to increased
transcription, gene amplification, and/or protein stabili-
zation. Yet, SKI may also exert anti-tumorigenic activ-
ities: for example, Ski+/- mice display an increased
susceptibility to chemical-induced tumorigenesis [30].
The human SKI gene is located at chromosome 1p36, a
potential tumor suppressor locus that is frequently
deleted in various human cancers including neuroblas-
toma, melanoma, colorectal carcinoma and leukemia
[31]. Clearly, the roles of SKI in mammalian tumorigen-
esis are complex, and more studies are needed in order
to define the functions of SKI.
Melanoma cells secrete large amounts of TGF-b:
expression of TGF-b1a n db2 is increased in parallel
with tumor stage, and all isoforms are expressed in
highly aggressive melanoma [32-34]. In melanoma cells,
constitutive SMAD signaling occurs in response to auto-
crine TGF-b secretion [35], and experimental blockade
of TGF-b signaling by SMAD7 overexpression dramati-
cally reduces their tumorigenic and metastatic potential
[36,37]. Likewise, systemic pharmacologic inhibition of
TGF-b signaling in mice prevents experimental mela-
noma cell metastasis to bone [38]. Remarkably, it has
been reported that melanoma cells express high
amounts of SKI protein, which localizes both in the
nucleus and in the cytoplasm [17]. It has been suggested
that such high expression of SKI blocks TGF-b tran-
scriptional responses, in particular the induction of p21/
WAF, resulting in an inactive TGF-b pathway in
melanoma cells and lack of growth inhibitory activity of
TGF-b [39,40]. SnoN may exert similar functions when
SKI is not expressed in some melanoma cell lines [41].
It is widely accepted that TGF-b is a potent inducer of
SKI (and SnoN) degradation [22-29], and we recently
demonstrated that in breast cancer cells, TGF-b sup-
presses the ability of SKI to inhibit tumor metastasis by
inducing its degradation via the ubiquitin-proteasome
pathway, whereby TGF-b induces the E3 ubiquitin-ligase
Arkadia to mediate SKI degradation in a SMAD-depen-
dent manner [22].
We report that despite high levels of SKI protein
expression, melanoma cells exhibit strong transcriptional
responses to TGF-b. We provide definitive evidence for
rapid and efficient dose-dependent degradation of SKI
protein in response to exogenous TGF-b,t h r o u g ht h e
ubiquitin-dependent proteasome pathway. Remarkably,
SKI antagonism against TGF-b activity primarily
occurred when SKI degradation in response to TGF-b
was prevented by proteasome blockade. We also report
that SKI levels do not correlate with the tumorigenic or
metastatic potential of melanoma cells, the latter largely
depending upon constitutive TGF-b signaling, and do
not correlate with the clinical or pathological stage of
human melanoma lesions.
Results
High SKI protein levels in human melanoma cell lines -
Absence of correlation with Matrigel™ invasiveness,
tumorigenicity or metastatic potential in vivo
We first used Western analysis to evaluate SKI and
SnoN protein levels in a panel of human melanoma cell
lines as compared to normal melanocytes. As shown
in Figure 1A, SKI and SnoN protein levels were
barely detectable in normal melanocytes. On the
other hand, all melanoma cell lines tested (WM793,
1205Lu, WM852, WM983B and SK28) expressed high
levels of SKI and SnoN protein (Figure 1A). The non-
tumorigenic MNT1 cell line expressed relatively similar
levels of SKI protein, after correction for b-actin con-
tent, as compared to other melanoma cell lines with
tumorigenic potential. Additional cell lines (Dauv-1, Fo-
1, WM239A, WM1341D, SK-mel501, SK-mel888) exhib-
ited similar high SKI protein content (not shown). These
data are consistent with previous report on the subject
[17]. P-SMAD3, a marker of constitutive TGF-b recep-
tor activity, was detected in all melanoma cell lines that
we examined, not in normal melanocytes, consistent
with our initial observations of autocrine SMAD signal-
ing in various human melanoma cell lines in culture
[35]. SKI mRNA levels, as measured using quantitative
RT-PCR (Figure 1B) were highly variable across mela-
noma cell lines, not higher than in normal melanocytes,
and did not correlate with SKI protein levels, suggesting
Javelaud et al. Molecular Cancer 2011, 10:2
http://www.molecular-cancer.com/content/10/1/2
Page 2 of 14uncoupling of gene transcription and protein expression.
Similar results were found for SnoN mRNA levels (not
shown). Together, these data are consistent with the lit-
erature that describes SKI and SnoN proteins as targets
for proteasomal degradation in response to TGF-b
[22-29].
We next examined the expression of the ubiquitin
ligases Arkadia and Smurf2, as these proteins are essen-
tial for proteasome-mediated degradation of SKI and
SnoN proteins. As shown in Figure 1C, all melanoma
cell lines exhibited elevated and rather similar levels of
Arkadia and variable levels of Smurf2. Arkadia was
hardly detectable in normal melanocytes, in which no
expression of Smurf2 was found. Remarkably, treatment
of normal melanocytes with the proteasome inhibitor
MG132 allowed for a dramatic recovery of SKI protein
levels (Figure 1D). MG132 treatment of 1205Lu
melanoma cells treated resulted in increased SKI protein
content, consistent with a role of the proteasome in
controlling SKI protein levels, both in normal and
malignant melanocytes.
Given our extensive phenotypic characterization of
various melanoma cell lines using Matrigel™ invasion in
vitro as well as subcutaneous tumor growth and bone
metastasis in nude mice [36,42], we thought to deter-
mine whether basal SKI protein levels in culture may be
predictive of a given invasive, tumorigenic, or metastatic
behavior of melanoma cells. As shown in Table 1, SKI
protein levels did not correlate with the capacity of mel-
anoma cells to invade Matrigel™. Neither did they corre-
late with their capacity to form subcutaneous tumors in
nude mice or with the incidence of bone metastasis fol-
lowing intracardiac inoculation of tumor cells into nude
mice. Remarkably, all of these cellular activities are
Figure 1 SKI and SnoN expression in human melanoma cell lines. A. Total protein extracts (40 μg) from unstimulated cultured melanoma
cell lines and normal melanocytes were analyzed by Western blotting for SKI, SnoN and P-SMAD3 levels. An anti-actin antibody served for
normalization. B. SKI mRNA steady-state levels, as measured by quantitative RT-PCR. C. Western analysis of the ubiquitin E3 ligases Arkadia and
Smurf2 levels in the same cell extracts as in panel A. D. 1205Lu at approx. 80% confluency were incubated for 8 h with MG132 (10 μM) before
protein extracts were prepared from cell lysates and processed for Western analysis of SKI content.
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SMAD7 overexpression or pharmacologic inhibitors of
TbRI kinase activity in vitro or in vivo [36-38], attesting
for pro-tumorigenic and pro-metastatic activities of
autocrine TGF-b signaling despite high SKI and SnoN
protein levels.
TGF-b signaling is a critical determinant of SKI protein
levels in melanoma cells
We next investigated whether high SKI levels in mela-
noma cells are associated with an absence of transcrip-
tional responses to TGF-b. Incubation of 1205Lu
melanoma cells with increasing concentrations of
TGF-b for 30 min lead to a dose-dependent decrease in
SKI protein content (Figure 2A), accompanied with an
inversely correlated increase in P-SMAD3 levels. Parallel
transient cell transfection experiments with SMAD3/
4-specific (CAGA)9-MLP-luc reporter construct indi-
cated dose-dependent transcriptional activation in
response to TGF-b (Figure 2B).
To determine the kinetics of SKI degradation in
response to TGF-b, three distinct human melanoma cell
lines that exhibit high SKI protein levels in basal cell
culture conditions were incubated with TGF-b; SKI pro-
tein content was monitored over time by Western blot-
ting. Results shown in Figure 2C indicate a rapid, time-
dependent, degradation of the SKI protein in all
cell lines, which was abolished when cells were incu-
bated with the TGF-b receptor type I (TbRI/ALK5)
kinase inhibitor SB431542 1 h prior to TGF-b addition
(Figure 2D).
In view of these experiments, it appears that despite
high expression of the SKI protein, melanoma cells
exhibit a strong transcriptional response to exogenous
TGF-b. Rapid degradation of SKI occurs within minutes
following TGF-b challenge and is accompanied with
strong SMAD-dependent transcriptional activity.
Inhibition of autocrine TGF-b signaling by stable
overexpression of SMAD7 in the 1205Lu cell line did
not significantly alter SKI protein content, yet dramati-
cally inhibited Matrigel™ invasion, and almost entirely
blocked subcutaneous tumor growth and the appearance
of experimental bone metastases in mice (Table 2),
Together, these results suggest uncoupling of the pro-
invasive and pro-metastatic activities of TGF-b with SKI
protein levels in melanoma cells, or at least indicate that
SKI function is relatively marginal as compared to the
tumor promoter activities of TGF-b
Proteasome blockade prevents SKI degradation in
response to TGF-b and attenuates TGF-b-driven
transcriptional responses
As expected from the literature, the proteasome inhibi-
tor MG132 efficiently abolished TGF-b-dependent SKI
degradation (Figure 3A). Also, a 1 h pre-treatment of
1205Lu and Dauv-1 melanoma cells with the protea-
some inhibitors MG132 and ALLN strongly inhibited
SMAD3/4-specific transcriptional response induced by
TGF-b in transient cell transfection experiments with
(CAGA)9-MLP-luc (Figures 3B and 3C, respectively).
Likewise, a 1-h pre-treatment with MG132 attenuated
TGF-b-induced IL-11 and PTHrP expression in 1205Lu
cells (Figures 3D and 3E, respectively), two known
SMAD genes targets implicated in melanoma and breast
cancer metastasis to bone [36,43-45]. Thus, although
SKI has little influence on TGF-b response because of
its rapid degradation, it is likely that prevention of
SKI degradation, as achieved by MG132 or ALLN pre-
treatment of the cells, contributes to the attenuation of
TGF-b-dependent transcriptional responses. This experi-
mental approach does not however exclude that other
proteasome-mediated events, independent from SKI,
may also be implicated in the attenuation of TGF-b
responses.
Stable SKI knockdown in 1205Lu melanoma cells neither
alters their invasive potential nor their response to TGF-b
To better understand the contribution of endogenous
SKI levels to melanoma cell behavior, SKI expression
was knocked down by stable expression in 1205Lu mela-
noma cells of a specific shRNA. Despite a 90% reduction
in SKI protein content (Figure 4A), there was no signifi-
cant alteration of SMAD3/4-specific transcriptional
responses to TGF-b, as estimated in transient cell trans-
fection experiments with (CAGA)9-MLP-luc (Figure 4B).
Likewise, induction of IL-11 and PTHrP expression in
response to TGF-b was not significantly altered in SKI-
knockdown cells as compared to mock-transfected cells
(Figure 4C). These data were further validated by means
Table 1 No correlation between SKI levels and melanoma
cell invasion, tumor growth and metastasis in mice
Cell line SKI
protein
levels
Matrigel™
invasion
Subcutaneous
tumor growth
in mice
Bone
metastases
in mice
SK28 100 8 90 40%
888mel 68 5 0 62.5
501mel 100 10 0 71.5
WM852 85 90 N.D. 100
1205Lu 65 100 95 100
Dauv1 53 20 50 100
Relative SKI protein levels in a series of cultured melanoma cell lines were
determined by scanning densitometry of Western analyses. Values for
subcutaneous tumor growth in mice represent tumor incidence at 40 days
post-injection. Matrigel™ invasion results are presented as relative values
compared to the 1205Lu cell line to which a value of 100 was given
arbitrarily. Values for bone metastases in mice represent the incidence at 5
weeks post-inoculation of tumor cells. Details about experimental procedures
may be found in [36,37]. N.D.: not determined.
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melanoma cells were incubated for 60 min. with increasing concentrations of TGF-b. Cell extracts were then prepared and subjected to Western
analysis for SKI and P-SMAD3 content. B. 1205Lu melanoma cells were transfected in triplicate dishes with (CAGA)9-MLP-luc and pRL-TK. Four
hours later, TGF-b was added at the indicated concentrations and reporter activity was measured 16 h later. Results are mean+/- SD from one
representative experiment. C. Three distinct human melanoma cell lines (501mel, 1205Lu and WM852) were incubated with TGF-b (10 ng/ml) for
various time periods. Cell extracts were prepared and subjected to Western analysis to determine SKI content. Actin was used as an internal
control. D. 1205Lu cells were incubated for 1 h in the absence (DMSO) or presence (SB) of the TbRI inhibitor SB431542 (5 μM) prior to addition
of TGF-b (10 ng/ml). Protein extracts were prepared 60 min later and subjected to Western analysis for SKI content.
Table 2 SMAD7 overexpression alters 1205Lu melanoma cell tumorigenicity and metastatic potential without altering
SKI levels
1205Lu
clones
SKI protein levels
(Western blotting)
Relative attenuation of TGF-b-dependent SMAD3/
4-specific transcriptional response
Matrigel™
invasion
Subcutaneous tumor
growth in mice
Bone
metastases in
mice
Pc 100 0 100 600 6/6 - 10/11
SMAD7a 82 70 55 nd 1/7 - 0/12
SMAD7b 107 50 45 nd 0/7 - 0/12
SKI protein levels in mock (pc) or SMAD7-overexpression 1205Lu cell populations (SMAD7a and SMAD7b) were determined by scanning densitometry of
corresponding Western analyses. Matrigel™ invasion results are expressed as % of the values obtained with mock-transfected cells. Values for subcutaneous
tumor growth in mice represent the average tumor volume 40 days after injection of tumor cells (mm
3). Values for bone metastases in mice represent the ratio
of mice bearing osteolytic bone metastases vs. total number of mice in each group at 5 weeks post-inoculation of tumor cells in 2 separate experiments. Details
about experimental procedures may be found in [36,37]. nd: not detectable.
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1205Lu, WM852 and 888mel cells (not shown). Also,
SKI knockdown did not alter the capacity of 1205Lu
and WM852 (not shown) melanoma cells to invade
Matrigel™ (Figure 4D).
These observations are consistent with the notion that
the high levels of SKI are effectively degraded by TGF-b
in these melanoma cells and therefore do not play a cri-
tical role in antagonizing, or preventing, TGF-b
responses. Accordingly, we previously provided direct
evidence that the invasive capacity of melanoma cells is
highly dependent upon autocrine TGF-b signaling [36],
further suggesting that SKI levels do not strongly influ-
ence or attenuate TGF-b effects.
SKI knockdown fails to restore TGF-b growth inhibitory
activity and p21 gene transactivation in melanoma cells
It has been suggested that high SKI expression in mela-
noma cells is responsible for the lack of growth inhibi-
tory activity of TGF-b, by blocking TGF-b-driven p21
expression [17,39]. Given the ample evidence for effi-
cient TGF-b signaling and associated transcriptional
responses in all melanoma cell lines tested thus far in
Figure 3 Proteasome blockade partially antagonizes TGF-b
activity and stabilizes SKI. A. 1205Lu cells were incubated for 1 h
in the absence (DMSO) or presence of the proteasome inhibitor
MG132 (10 μM) prior to addition of TGF-b (10 ng/ml). Protein
extracts were prepared 60 min later and subjected to Western
analysis for SKI content. B, C. 1205Lu (panel B) and Dauv-1 (panel C)
melanoma cells were transfected in triplicate dishes with (CAGA)9-
MLP-luc and pRL-TK. 4 h later, cells were incubated with either
DMSO, MG132 or ALLN 1 h prior to the addition of TGF-b (10 ng/
ml). Reporter activity was measured 16 h later. Results are mean+/-
SD from one representative experiment. D, E. 1205Lu melanoma
cells were incubated with either DMSO or MG132 1 h prior to the
addition of TGF-b (10 ng/ml). RNA was extracted 8 h later. IL-11
(panel D) and PTHrP (panel E) expression was measured by
quantitative RT-PCR.
Figure 4 Effects of stable SKI knockdown in 1205Lu melanoma
cells. A. Western analysis of SKI protein content in mock-transfected
(Ø) and shSKI-transfected 1205Lu cells. B. Subconfluent melanoma
cells were transfected with (CAGA)9-MLP-luc together with pRL-TK
to measure transfection efficiency. Four hours post-transfection,
cultures were left untreated (-) or stimulated (+) with TGF-b (10 ng/
ml). Luciferase activities were measured in cell extracts 16 h post-
transfection. C. Mock (Ø) and shSKI-transfected 1205Lu melanoma
cells were incubated with TGF-b (10 ng/ml). RNA was extracted 8 h
later. IL-11 and PTHrP expression was measured by quantitative RT-
PCR. GAPDH mRNA levels served as internal controls. D. Comparative
analysis of Matrigel™ invasion by mock- (Ø) and shSKI-transfected
1205Lu melanoma cells. Experiments were performed four times
using duplicate samples.
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reproduce these data in the 1205Lu melanoma cell line,
which is both highly invasive, strongly resistant to
TGF-b growth inhibitory activity, capable of a strong
SMAD3/4-specific transcriptional response to exogenous
TGF-b stimulation, yet expresses high levels of SKI and
SnoN proteins (see Figure 1A). Firstly, parallel transient
cell transfections with either a 2.4-kb p21/WAF1 promo-
ter luciferase construct or (CAGA)9-MLP-luc were per-
formed in 1205Lu cells. TGF-b had no effect on p21
promoter activity despite efficient SMAD3/4-specific
gene transcription, as measured using the highly sensi-
tive (CAGA)9-MLP-luc construct (Figure 5A). As
expected, p21 promoter transactivation in response to
TGF-b was readily observed in HaCaT keratinocytes.
These data confirm our initial observations that mela-
noma cells efficiently respond to TGF-b b yas t r o n g
SMAD-specific transcriptional response [35-37], and
that the lack of induction of p21 is highly gene-specific
and is probably not due to a general inhibition of
TGF-b signaling by SKI or SnoN, as SMAD3/4-specific
transcription and induction of other TGF-b target
genes, such as IL-11 or PTHrP, is intact. Remarkably,
both the proliferative rate and the weak growth inhibi-
tion exerted by TGF-b (approx. 10% after 72 h) were
virtually identical in both mock- and shSKI-transduced
1205Lu cells (Figure 5B). Also, SKI knockdown did not
restore p21 promoter transactivation in response to
TGF-b (Figure 5C). Likewise, oligonucleotide siRNA-
mediated SKI knockdown in transient cell transfection
experiments using 1025Lu, WM852 and 888mel cells did
not allow p21 expression or promoter transactivation in
response to TGF-b in any of those cell lines (not shown).
These results are fully consistent with our previous work
and with the observations provided herein that indicate
that high SKI levels in melanoma cells do not antagonize
the pro-tumorigenic activities exerted by TGF-b. Neither
do they interfere with TGF-b-driven gene responses. It
should be noted that lack of p21 induction by TGF-b in
1205Lu cells is specific, as we previously demonstrated
that JNK inhibition efficiently activates p21 expression
and promoter transactivation in this cell line [46].
SKI expression in human melanocytic lesions
Relatively few studies have examined the expression of
SKI in melanocytic lesions in humans. We thus used
immunohistochemistry to detect SKI protein in a panel
of 12 nevi, 37 primary melanomas at various clinical
and pathological stages of disease progression, 17 cuta-
neous and 10 lymph node metastases (Table 3). SKI was
detected in 8 (66%) nevi, 8 (21.6%) primary melanomas,
and 8 (21.7%) metastases (Table 4). Representative
results for SKI staining are shown in Figure 6. We
f o u n dn oe v i d e n c ef o ral i n kb e t w e e nS K Ie x p r e s s i o n
and histological or pathological staging within each mel-
anoma group of samples. These data are remarkably
similar to those recently reported in a larger cohort of
120 patients treated for cutaneous melanoma [47].
We further analyzed the activation of TGF-b signaling
in tissues by means of P-SMAD3C immunohistochemis-
try in a subset of melanomas and metastases. Nuclear
expression of P-SMAD3C was observed in all melanocy-
tic lesions, albeit at varying intensity (Figure 7). Intrigu-
ingly, staining intensity of SKI and phospho-SMAD3C
on consecutive sections appeared to be inversely
Figure 5 Stable SKI knockdown in 1205Lu melanoma cells
does not restore the growth inhibitory activity of TGF-b.A .
Subconfluent 1205Lu melanoma cell or HaCaT keratinocyte cultures
were transfected in parallel with either a 2.4 kb p21/WAF1 reporter
construct (left panel) or (CAGA)9-MLP-luc (right panel), together with
pRL-TK to measure transfection efficiency. Four hours post-
transfection, cultures were left untreated (-) or stimulated (+) with
TGF-b (10 ng/ml). Luciferase activities were measured in cell extracts
16 h post-transfection. B. Proliferation of mock- (Ø) and shSKI-
transfected 1205Lu cells in the absence (-) or presence (+) of TGF-b
(10 ng/ml). C. Mock- (Ø) and shSKI-transfected 1205Lu melanoma
cells were transfected in triplicate dishes with p21-luc and pRL-TK.
TGF-b (10 ng/ml) was added 4 h later. Reporter activity was
measured 16 h later. Results are mean+/- SD from one
representative experiment.
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chemical analyses do not allow quantification of protein
expression, they support our observation that high
TGF-b signaling can drive SKI degradation.
Taken together, the results presented herein unam-
biguously demonstrate (a), that SKI levels in melanoma
cells are not predictive of their tumorigenic, invasive or
metastatic propensity, (b), that TGF-b signals lead to
rapid degradation of SKI proteins in a proteasome-
dependent manner, and (c), that TGF-b induces a effi-
cient SMAD3/4-dependent transcriptional response in
melanoma cells despite high expression of c-SKI and
SnoN in these cells. Furthermore, our results support
the notion that there is no correlation between SKI
expression and tumor progression or histogenetic sub-
type of human cutaneous melanomas.
Discussion
The capacity for SKI (and SnoN) to inhibit TGF-b sig-
naling has been extensively described. This has
prompted us to consider that SKI proteins may exert
tumor promoter activities, by preventing the classical
growth inhibitory activity exerted by TGF-b in a variety
of non-malignant cell types. Most experimental demon-
strations for interference of SKI against TGF-b/SMAD
signaling have largely relied on either overexpression or
stabilization (by means of proteasome inhibition) of the
SKI and SnoN proteins, due to the fact that TGF-b is
able to rapidly induce SKI degradation in a proteasome-
dependent manner [22-29]. Remarkably, in a number of
neoplasms, high SKI and/or SnoN protein levels in
tumor cells are observed, concomitant with (a), elevated
levels of secreted TGF-b and (b), a great sensitivity of
tumor cells to targeted inhibition of TGF-b signaling
that strongly interferes with their tumorigenic and meta-
static potential. This study was thus initiated in order to
clarify the discrepancy in the literature regarding the
respective roles played by TGF-b signaling and that of
potentially antagonistic SKI proteins in the control of
the invasive and metastatic capacities of human mela-
noma cells.
W e ,a n do t h e r s ,h a v ep r o v i d e da m p l ee v i d e n c et h a t
the invasive, tumorigenic and metastatic potential of
melanoma cell lines is largely dependent upon autocrine
TGF-b signaling. We showed initially that the SMAD
cascade is activated in an autocrine fashion in a series of
Table 3 Clinical and histopathological characteristics of a panel of human melanocytic lesions
Number (%) Mean (95% CI)
Nevi (n = 12)
Gender Male 6 (50.0%)
Female 6 (50.0%)
Age at Diagnosis (years) 36.9 (29.9-43.8)
Primary melanoma (n = 37)
Gender Male 17 (45.9%)
Female 20 (54.1%)
Age at Diagnosis (years) 56.5 (50.3-62.6)
Anatomic localization Head&Neck 3 (8.1%)
Trunk 17 (45.9%)
Extremities 17 (45.9%)
Growth pattern SSM 31 (83.8%)
NM 3 (8.1%)
ALM 3 (8.1%)
Level of invasion (Clark) II 9 (24.3%)
III 9 (24.3%)
IV 13 (35.1%)
V 6 (16.2%)
Thickness (mm) 1.80 (1.21-2.39)
Metastases (n = 27)
Gender Male 19 (70.4%)
Female 8 (29.6%)
Age at Diagnosis (years) 55.5 (50.5-60.6)
Site Cutaneous 17 (63.0%)
Lymph node 10 (37.0%)
Formaldehyde-fixed and paraffin-embedded nevi (n = 12), primary cutaneous melanomas (n = 37), cutaneous and lymph node metastases (n = 17 and 10,
respectively) from adult patients from the pathology archives of the Radboud University Nijmegen Medical Centre were re-evaluated by an expert pathologist.
Abbreviations: SSM, superficial spreading melanoma; NM: nodular melanoma; ALM: acral lentiginous melanoma.
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overexpression of SMAD7 in a highly invasive and
metastatic cell line, 1205Lu, inhibits subcutaneous
tumor growth as well as incidence and size of osteolytic
bone metastases in mice, accompanied with dramatically
increased survival [36,37]. Consistent with our observa-
tions, Lo and Witte [48] identified intense nuclear
immunohistochemical staining of P-SMAD2 in benign
nevi, melanoma in situ, and primary invasive melanoma,
suggesting that the tumor cell autonomous TGF-b path-
way is hyperactivated in response to autocrine and/or
paracrine ligand activity. They demonstrated that tumor
cell autonomous hyperstimulation of the TGF-b-
SMAD2 pathway is causally related to melanocytic
oncogenic progression in the skin and is responsible, at
least in part, for the critical switch from radial to verti-
cal growth during human melanoma histogenesis. They
showed that this phenomenon requires the collaboration
of activated SMADs with an altered genetic or epige-
netic cellular context such as PTEN deficiency or
MAPK activation [48]. Considering recent findings
showing that (a) TGF-b could act of in SMAD2,
SMAD3 and SMAD4-independent manner and present
pro-oncogenic activity through enhancement of Ras/Raf
tumorigenic transformation [49], and (b) majority of
examined melanoma cells harbor activating muta-
tion in BRAF and NRAS (BRAF V600E in WM793,
1205Lu, 983B) (NRAS Q61R in WM852), it is likely that
TGF-bpromotes tumor progression through the
enhancement of SKI-independent pathways, possibly
MAP kinases [50]. Our data on Matrigel™ invasion
Figure 7 Phospho-SMAD3C and SKI expression in melanoma.
Consecutive slides of two cutaneous melanoma metastases (A, B and
C, D) were stained for phospho-SMAD3C (A, C) and SKI (B, D). The
intense P-SMAD3C (A) and lack of SKI staining (B) in the first sample
contrasts with the relatively low P-SMAD3C staining (C) associated
with clear nuclear SKI staining (D) from the other sample, and
suggests an inverse correlation between both staining intensities.
Arrows in D indicate SKI-positive nuclei. Scale bars: 12,5 μm.
Table 4 SKI detection in a panel of human melanocytic
lesions
SKI expression
Absent Present p-Value
Nevi (n = 12) 4 8 0.388
a
Primary melanoma (n = 37)
Tumor thickness Mean (mm) 1.68 2.2
95% CI 1.02-2.35 0.63-3.78 0.427
b
Level of invasion (Clark) II 8 1
III 7 2
IV 10 3
V 4 2 0.779
c
all 29 (74.4%) 8 (21.6%)
Growth pattern SSM 24 7
NM 2 1
ALM 3 0 0.581
c
Anatomical localization Head&Neck 2 1
Trunk 13 4
Extremities 14 3 0.803
c
Metastases (n = 27)
Site Lymph node 7 3
Skin 12 5 0.651
d
Abbreviations: SSM, superficial spreading melanoma; NM: nodular melanoma;
ALM: acral lentiginous melanoma.
a: binominal test;
b: Mann-Whitney U;
c: Pearson Chi-square;
d: Fisher exact test.
Figure 6 SKI expression in melanocytic lesions.N e v u s( A ,B )
without nuclear staining. Clear reddish/purple nuclear staining in
primary melanoma (C, D) and weak, though evident, nuclear
staining in a cutaneous metastasis (A, F). Arrows in D and E indicate
SKI-positive nuclei. A, C, E: H&E staining. Scale bars A, C, E: 50 μm; B,
D, F: 12,5 μm.
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activities.
The functional response of melanoma cells to TGF-b
has been addressed by a number of laboratories. For
example, it has been shown that TGF-b is a potent
inducer of integrins, IL-8,a n dVEGF gene expression
[51-54], genes implicated in metastasis and tumoral
angiogenesis, respectively. A genome-wide transcrip-
tomic analysis in over a hundred human melanoma cell
lines in culture recently identified populations with very
distinct gene expression profiles, the most invasive cell
lines being characterized by the expression of a number
of genes reminiscent of a TGF-b signature [55].
Comparable levels of expression of SKI although there
is almost complete lack of the SKI protein in normal
melanocytes as compared to melanoma suggest that
degradation of SKI protein in normal melanocytes is far
more efficient than in malignant cells and involves an
alternative, yet unidentified, TGF-b-independent
mechanism of SKI degradation (or translation) and that
this mechanism is deregulated in melanoma cells.
The pro-metastatic role of TGF-b extends well beyond
melanoma and has been extensively described in
other cancers, including, but n o tr e s t r i c t e dt o ,g l i o m a s ,
breast, ovarian, colon, or prostate adenocarcinomas
[44,45,56-58]. The TGF-b pathway is thus considered a
prime target for preventive or therapeutic intervention
in cancer [59-65]. Remarkably, Nodal, a TGF-b family
member that also signals through the SMAD pathway,
has been identified as playing a crucial role in mela-
noma progression and metastasis [66]. It is thus highly
likely that increased availability of TGF-b ligands cap-
able of activating the SMAD pathway will either bypass
or overcome the inhibitory action exerted by SKI pro-
teins, despite apparent high expression of the latter.
Our data are consistent with those reported by
Medrano and co-workers [17,39] that melanoma cells in
culture and human melanoma lesions exhibit high SKI
protein levels. Yet, we differ significantly regarding the
importance of this high of SKI in determining mela-
noma growth and metastasis. Our data obtained in a
large panel of melanoma cell lines suggest that SKI only
marginally affects TGF-b signaling: slightly elevated
basal expression of some of the classical TGF-b target
genes, like PTHrP and IL-11,w a so b s e r v e di ns h S K I -
transfected 1205Lu melanoma cells as compared to
mock-transfected cells, yet SKI knockdown only margin-
ally affected the response to TGF-b, as estimated both
at the level of target gene transcription and cell prolif-
eration. While Reed and colleagues argued that SKI is
crucial for the resistance of melanoma cells to TGF-b-
induced growth inhibition and subsequent tumor
growth [17,39], their data were largely obtained with the
UCD-Mel-N cell line, and thus could be specific for this
cell line or for a subset of melanoma cell lines, and may
not be representative of all melanoma cells at large.
Noteworthy, when we initially reported that autocrine
SMAD signaling occurs in melanoma cells and is depen-
dent upon secretion and pericellular activation of TGF-b
[35], we did not know the expression status of SKI and
SnoN protein in the various cell lines used in our stu-
dies. In the present study, we demonstrate that auto-
crine TGF-b signaling is active despite high levels of
SKI and SnoN protein in all melanoma cell lines (11)
that we examined, including those from our initial stu-
dies. Thus, our data unambiguously demonstrate that
the presence of high SKI levels is compatible with active
TGF-b signaling, implying that high SKI staining in
tumors may not be an indication of an absence of TGF-
b-driven disease progression, as exemplified by studies
with inhibitors of the TGF-b pathway that efficiently
prevent melanoma tumorigenesis and metastasis
[36-38]. It is possible that a subgroup of melanomas
may reproduce the data obtained by Medrano and
co-workers, as a similar observation was reported in a
subset of esophageal carcinoma cells that are resistant
to TGF-b-induced growth arrest, whereby TGF-b was
unable to degrade SnoN [67].
Most critically, Chen and co-workers suggest that SKI
should be considered a prime therapeutic target for mel-
anoma treatment [39], as eliminating SKI protein would
unleash the growth inhibitory activity of TGF-b.S u c h
suggestion was recently echoed in a clinical report on
the expression of SKI and SnoN in human melanoma
lesion at various stages [47]. While these authors
demonstrated that SKI and SnoN expression in mela-
noma is not associated with disease progression, they
extrapolated, without experimental evidence, that SKI
and SnoN may mediate the resistance of melanomas to
growth inhibition by TGF-b. In our opinion, critical and
potentially dangerous issues arise from the assumption
that melanoma cells are not responsive to TGF-b:a t
advanced stages of tumor progression, therapeutic inter-
ference with invasion and metastasis, two phenomena
that do not require cell proliferation and are largely
under the control of TGF-b, is likely to prove essential.
Targeting SKI, even though in some instance it may
allow some reduction in tumor cell growth, as suggested
by Medrano’s group, may just do the opposite, as it
would eliminate one of the natural defenses that cells
have developed to interfere with autocrine TGF-b sig-
nals. Noteworthy, discrepancies about the capacity of
TGF-b to degrade SKI in melanoma cells have been sug-
gested to be due to the concentrations of TGF-b used in
the various studies, and that TGF-b-induced SKI degrada-
tion only occurs at “non-physiological” concentrations [68].
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suggestion, increasing concentrations of TGF-b would
eliminate SKI and thus exert its anti-proliferative activity
and inhibit tumor progression, in contradiction with
experimental evidence that inhibition of TGF-b signaling
inhibits melanoma progression and metastasis. Note-
worthy, given that TGF-b blockade inhibits metastasis,
then whatever active concentration is present is effective to
promote metastasis in spite of possible high levels of SKI
expression.
Conclusions
We provide evidence that despite high levels of c-SKI
(and SnoN) oncoproteins in melanoma cells, TGF-b sig-
naling is functional and contributes to melanoma cell
invasiveness and metastasis. Exogenous TGF-b induces
a rapid, proteasome-mediated, degradation of c-SKI, not
accompanied by an inhibitory activity of TGF-b on mel-
anoma cell proliferation. While understanding the exact
role played by labile c-SKI protein in melanoma remains
to be understood, we believe that targeting SKI to pre-
vent tumor spreading and disease progression is likely
not an appropriate therapeutic strategy.
Methods
Cells, plasmids and reagents
Melanoma cell lines (1205Lu, WM852, WM983B, SK28,
MNT1, Dauv-1, Fo-1, WM239A, WM1341D, SK-
mel501, SK-mel888) have been described previously
[35,42,69-71]. NHEM (Normal Human Epidermal Mela-
nocytes) were purchased from Promocell (Heidelberg,
Germany) and cultured in ready-to-use medium, also
supplied by Promocell. All cells were grown at 37°C in a
humidified atmosphere of 5% CO2. The reporter plas-
mids (CAGA)9-MLP-luc [72] and 2.4 kb p21/WAF1
promoter luciferase reporter construct [73] were gifts
from Drs. Sylviane Dennler (INSERM U697, Paris,
France) and Bert Vogelstein (Johns Hopkins University,
Baltimore, MD), respectively. The pRL-TK vector was
from Promega (Madison, WI). pSuper vector expressing
SKI shRNA has been described previously [22]. Human
recombinant TGF-b1, purchased from R&D System Inc.
(Minneapolis, MN) is referred to as TGF-b throughout
the text. The ALK5/TbRI inhibitor SB431542, and
the proteasome inhibitor leu-leu-leu-al (MG132) were
both from Sigma-Aldrich (St. Louis, MO). Acetyl-leu-
leu-norleu-al (ALLN) was purchased from CalBiochem
(San Diego, CA).
Immunoblotting experiments
Protein extraction and Western blotting were performed
as previously described [74]. Anti-SMAD3 and anti-
Actin antibodies were purchased from Zymed (San
Francisco, CA) and Sigma-Aldrich, respectively. The
rabbit anti-phospho-SMAD3 antibody [75] was a gener-
ous gift from Dr. Edward Leof (Mayo Clinic College of
Medicine, Rochester, MN). Anti-c-SKI, anti-SnoN, anti-
SMURF2, anti-HSP60 and secondary anti-mouse and
anti-rabbit horseradish peroxidase-conjugated antibodies
were from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Anti-Arkadia was obtained from Abnova Gmbh
(Heidelberg, Germany).
Cell transfections and luciferase assays
Melanoma cells were seeded in 24-well plates and trans-
fected at approximately 80% confluency with the polyca-
tionic compound Fugene (Roche Diagnostics,
Indianapolis, IN) in fresh medium containing 1% FCS.
TGF-b and/or inhibitors were added 4 h after transfec-
tions. Following a 16-h incubation, cells were rinsed
twice with PBS and lysed in passive lysis buffer (Pro-
mega). pRL-TK (Promega) was co-transfected to assess
transfection efficiency. Luciferase activities were deter-
mined with a Dual-Glo luciferase assay kit according to
the manufacturer’s protocol (Promega). Each experiment
was repeated at least three times using triplicate dishes
in each of them for each experimental condition.
RNA extraction and gene expression analysis
Total RNA was isolated using an RNeasy™ kit (Qiagen
GmbH, Hilden Germany). Genomic DNA contamina-
tions were eliminated by DNAse I treatment. One micro-
gram of RNA from each sample was reverse transcribed
using the Thermoscript kit (InVitrogen) following the
manufacturer’s protocol. The resulting cDNAs were then
processed for either semi-quantitative or real-time PCR
using SYBR Green technology. In the latter case, reac-
tions were carried out in a 7300 Real-time PCR System
(Applied Biosystem) for 40 cycles (95°C for 15 sec/60°C
for 1 min) after an initial 10-min incubation at 95°C,
using the following primer sets: SKI (sense, 5’-gagaaattc-
gactatggcaacaag-3’; antisense, 5’-gtcatctgttttgggtcttatgga-
3’; IL-11 (sense, 5’-actgctgctgctgaagactc-3’;a n t i s e n s e ,
5’-ccacccctgctcctgaaata-3’); PTHrP (sense, 5’-tttacggcgac-
gattcttcc-3’; antisense, 5’-ttcttcccaggtgtcttgag-3’); GAPDH
(sense, 5’-gctcctcctgttcgacagtca-3’;a n t i s e n s e ,5 ’-accttcc
ccatggtgtctga-3’). Data were analyzed using Applied
Biosystems Sequence Detection Software (version 1.2.1).
Matrigel™ invasion assays
Tissue culture Transwell
® inserts (8-μm pore size, Falcon,
Franklin Lakes, NJ) were coated for 3 h with 10 μgo f
growth factor-reduced Matrigel™ (Biocoat, BD Bios-
ciences, San Jose, CA) in 100 μl of PBS at 37°C. After
air-drying the chambers for 16 h, the Matrigel™ barrier
was reconstituted with 100 μl DMEM for 24 h at 37°C.
The chambers were then placed into 24-well dishes con-
taining 750 μl of W489 medium supplemented with 0,1%
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4) were added to the upper well of each
chamber in 500 μl of serum-free W489 medium. After a
24 h-incubation period, the number of invading cells was
counted by bright-field microscopy at ×200 in six random
fields. Additional details of the procedure may be found
in [37].
Cell proliferation assays
Melanoma cells were plated in 12-well plates at an
initial density of 5000 cells/well. Cell growth was mea-
sured after 72 h in 1% FCS, with or without TGF-b
(10 ng/ml), by counting the cells after trypsinization
using a Malassez cell. For each experimental condition,
duplicate dishes were counted. Experiments were per-
formed at least three times with similar results.
Human tissues
Formaldehyde-fixed and paraffin-embedded naevi
(n = 12), primary cutaneous melanomas (n = 37), cuta-
neous and lymph node metastases (n = 17 and 10,
respectively) from adult patients were obtained from the
pathology archives of the Radboud University Nijmegen
Medical Centre, and re-evaluated by an expert patholo-
gist (see corresponding Results section for details). Tis-
sues were obtained according to local ethical guidelines
and approved by the local regulatory committee.
Immunohistochemistry
Paraffin-embedded 4 μm sections on superfrost slides
(Menzel-Glaser, Braunscheig, Germany) were de-waxed
in xylene, rehydrated through graded alcohol baths, then
rinsed with PBS. After quenching of endogenous peroxi-
dases, an antigen retrieval step (sodium citrate 10 mM,
pH 6.0 for 10 min. at 95°C) was performed. Tissue sec-
tions were subsequently pre-incubated with 20% normal
goat serum in PBS, followed by an overnight incubation
with rabbit polyclonal SKI antibody (H-329, 1 μg/ml,
Santa Cruz Biotechnology Inc.) or affinity-purified rabbit
polyclonal anti-phospho-Smad3C (P-SMAD3C) antibody
[75] in PBS containing 1% bovine serum albumin over-
night at 4°C. For detection of SKI, the Powervision sys-
tem (Immunovision Labs, Brisbane, CA) was used as a
secondary reagent with 3-amino-9-thylcarbazole served
as a chromogen. For detection of P-SMAD3C, a biotin-
avidin peroxidase complex was generated according to
standard procedures (Vector, Burlingame, CA) and
developed with 3,3’-diaminobenzidine. Counterstaining
was performed with hematoxylin. Samples with nuclear
SKI appear purple and were scored positive in case posi-
tivity was detected in at least 10% of melanocytic cells.
Statistical analyses
Data were entered in a computerized database and ana-
lyzed using SPSS software (version 16.0.1 for Windows).
The binomial test was used to analyze frequency of SKI
expression in nevi. The Mann-Whitney U test was used
to correlate SKI expression and tumor thickness. The
correlation between SKI expression and the level of
invasion was determined by the Pearson Chi-square test.
Fisher exact test for small sample numbers was used to
determine the correlation between SKI expression in
cutaneous and nodal metastases.
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